Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

Last updated: May 28, 2024
Sponsor: Affiliated Hospital of Nantong University
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Nasopharyngeal Cancer

Carcinoma

Treatment

Tocilizumab Asprin

Placebo

Clinical Study ID

NCT06442709
2023-K015
  • Ages 20-70
  • All Genders

Study Summary

The investigators have demonstrated the crucial role of the liver-lung axis in the distant metastasis of NPC. Furthermore, the investigators have identified a potential therapeutic approach to improve outcomes in NPC patients by identifying those most suitable for anticoagulant therapy. Further, the combination of anticoagulant therapy and anti-IL6R therapy has shown promising results in enhancing the prognosis of NPC patients. These findings highlight the significance of targeting the liver-lung axis and utilizing personalized treatment strategies for NPC.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Clinical diagnosis of NPC with distant metastasis

  • Must be able to swallow tablets

Exclusion

Exclusion Criteria:

  • Liver disease

  • Blood disease

  • Long-term use of anticoagulants

Study Design

Total Participants: 100
Treatment Group(s): 2
Primary Treatment: Tocilizumab Asprin
Phase:
Study Start date:
August 01, 2021
Estimated Completion Date:
July 01, 2024

Study Description

Distant metastasis accounts for nasopharyngeal carcinoma (NPC)-related mortalities. Recently, extracellular vesicles (EVs) have been widely explored as key mediators of bidirectional tumor-host cell interactions by mediating pre-metastatic niche (PMN) formation. However, considering the complexity of the human body, multiple organ studies of tumor metastasis remain poorly understood. Here, the investigators have demonstrated the crucial role of the liver-lung axis in the distant metastasis of NPC. The investigators demonstrated mechanistically that hepatocellular derived EVs can be specifically taken up by the lung to form a hypercoagulable pre-metastatic microenvironment associated with IL6.Furthermore, the investigators have identified a potential therapeutic approach to improve outcomes in NPC patients by identifying those most suitable for anticoagulant therapy. Further, the combination of anticoagulant therapy and anti-IL6R therapy has shown promising results in enhancing the prognosis of NPC patients. These findings highlight the significance of targeting the liver-lung axis and utilizing personalized treatment strategies for NPC.

Connect with a study center

  • Bo You

    Nantong, Jiangsu 226000
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.